---
title: Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder
nct_id: NCT07480525
overall_status: NOT_YET_RECRUITING
phase: NA
sponsor: Peking University
study_type: INTERVENTIONAL
primary_condition: Depression - Major Depressive Disorder
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07480525.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07480525"
ct_last_update_post_date: 2026-03-18
last_seen_at: "2026-05-12T06:01:19.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder

**NCT ID:** [NCT07480525](https://clinicaltrials.gov/study/NCT07480525)

## Key Facts

- **Status:** NOT_YET_RECRUITING
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 200
- **Lead Sponsor:** Peking University
- **Collaborators:** The First Hospital of Hebei Medical University, First Hospital of China Medical University, Shandong Mental Health Center, Hebei Provincial Mental Health Center
- **Conditions:** Depression - Major Depressive Disorder
- **Start Date:** 2026-03-20
- **Completion Date:** 2026-12-31
- **CT.gov Last Update:** 2026-03-18

## Brief Summary

The goal of this project is to quantify the effectiveness and safety of escitalopram oxalate oral solution in the treatment of first-episode, drug-naïve patients with major depressive disorder, and to explore the mechanisms underlying its antidepressant effects using multi-omics approaches. By integrating clinical, cognitive, laboratory, imaging, genetic, and environmental data, the study aims to identify patient subgroups who are most likely to benefit from escitalopram, thereby promoting individualized and precision treatment for depression.

This multicenter, prospective, single-arm intervention study will enroll 200 adults aged 18-65 years with major depressive disorder, who will receive escitalopram oxalate oral solution for 8 weeks. Depressive symptoms, cognitive function, and adverse events will be assessed at baseline, during treatment, and after 8 weeks of treatment to evaluate efficacy and safety. Escitalopram blood concentrations will be measured at week 4 to monitor treatment adherence and support safety evaluation. Through comprehensive data collection and multimodal analysis, this project seeks to clarify the biological mechanisms of escitalopram and provide evidence to guide more precise clinical use of antidepressant therapy.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 65 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Aged 18-65 years (including 18 and 65), no gender restriction, Han Chinese ethnicity.
2. Meets the diagnostic criteria for depressive disorders according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), confirmed by the Mini-International Neuropsychiatric Interview, version 5.0 (MINI).
3. Outpatients or inpatients; Hamilton Depression Rating Scale-17 items (HAMD-17) score ≥17; Hypomania Checklist-32 (HCL-32) score ≤13; and Clinical Global Impressions-Severity (CGI-S) score ≥4.
4. First depressive episode (duration ≤3 months), with no use of antidepressants or other psychotropic medications in the past 3 months.
5. Written informed consent obtained from the patient.

Exclusion Criteria:

1. Meet DSM-IV diagnostic criteria other mental disorders, including schizophrenia spectrum and other psychotic disorders, bipolar and related disorders, obsessive-compulsive disorder, etc..
2. Individuals with intellectual disabilities or who are unable to cooperate for other reasons, or those lacking or having incomplete civil capacity during the onset of illness;
3. Suffering from neurological or organic brain diseases (such as stroke, cerebral hemorrhage, brain tumors, Parkinson's disease, epilepsy, etc.) and a history of severe traumatic brain injury;
4. Have attempted suicide within the past 3 months, or currently present a high suicide risk, defined as a Montgomery-Åsberg Depression Rating Scale (MADRS) item 10 score ≥5.
5. Are pregnant or breastfeeding, cannot use reliable contraception during the study, or plan to conceive (or impregnate a partner) within 3 months after study initiation.
6. Have known allergies to escitalopram oxalate or its excipients.
7. Are currently taking medications that may interfere with the evaluation of escitalopram efficacy.
8. Have participated in another drug clinical trial within the past 3 months.
9. Have contraindications to MRI scanning, such as metal implants or claustrophobia.
10. Considered unsuitable for study participation by the investigators for any other reason.
```

## Arms

- **Escitalopram** (EXPERIMENTAL) — Participants will receive escitalopram oral solution as open-label monotherapy.

## Interventions

- **Escitalopram (Oral antidepressant)** (DRUG) — Participants will receive escitalopram oral solution as open-label monotherapy.

## Primary Outcomes

- **Change from baseline in Hamilton Depression Rating Scale (HAMD)** _(time frame: Week 4 and 8 of treatment duration)_ — The outcome is assessed by 17-item Hamilton Depression Rating Scale (HAMD-17) Scale. Total HAMD scores range from 0 to 24, with higher scores indicating more severe depressive symptoms. The change of HAMD from baseline to 8-week (after intervention) was used as the primary outcome.

## Secondary Outcomes

- **Change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS)** _(time frame: Week 4 and 8 of treatment duration)_
- **Response to treatment** _(time frame: Week 4 and 8 of treatment duration)_
- **Clinical Global Impression-Severity of Illness (CGI-S)** _(time frame: Baseline; Week 4 and 8 of treatment duration)_
- **Change from baseline in C-BCT score** _(time frame: Week 4 and 8 of treatment duration)_
- **Change from baseline in Hamilton Anxiety Rating Scale (HAMA)** _(time frame: Week 4 and 8 of treatment duration)_
- **Treatment Emergent Symptom Scale (TESS)** _(time frame: Baseline; Week 4 and 8 of treatment duration)_
- **Escitalopram Therapeutic drug monitoring** _(time frame: Week 4 of treatment duration)_
- **Change from baseline in Snaith-Hamilton Pleasure Scale (SHAPS)** _(time frame: Week 4 and 8 of treatment duration)_
- **The Temporal Experience of Pleasure Scale (TEPS)** _(time frame: Week 4 and 8 of treatment duration)_
- **Childhood Trauma Questionnaire (CTQ)** _(time frame: Baseline)_
- **Change from baseline in Ruminative Responses Scale (RRS)** _(time frame: Week 4 and 8 of treatment duration)_
- **Change from baseline in Pittsburgh Sleep Quality Index (PSQI)** _(time frame: Week 4 and 8 of treatment duration)_
- **Change from baseline in Connor-Davidson Resilience Scale (CD-RISC)** _(time frame: Week 4 and 8 of treatment duration)_
- **Biomarkers level** _(time frame: Week 0 and 8 of treatment duration)_
- **Brain imaging features** _(time frame: Week 0 and 8 of treatment duration)_

## Locations (5)

- Peking University Sixth Hostipal, Beijing, Beijing Municipality, China
- Hebei Provincial Mental Health Center, Baoding, Hebei, China
- The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
- The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
- Shandong Mental Health Center, Jinan, Shandong, China

## Recent Field Changes (last 30 days)

- `eligibility.criteria` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.peking university sixth hostipal|beijing|beijing municipality|china` — added _(2026-05-12)_
- `locations.hebei provincial mental health center|baoding|hebei|china` — added _(2026-05-12)_
- `locations.the first hospital of hebei medical university|shijiazhuang|hebei|china` — added _(2026-05-12)_
- `locations.the first affiliated hospital of china medical university|shenyang|liaoning|china` — added _(2026-05-12)_
- `locations.shandong mental health center|jinan|shandong|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07480525.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07480525*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*